KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Equity Average (2017 - 2025)

Moderna (MRNA) has disclosed Equity Average for 8 consecutive years, with $9.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 21.24% to $9.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.0 billion, a 21.24% decrease, with the full-year FY2025 number at $9.8 billion, down 21.02% from a year prior.
  • Equity Average was $9.0 billion for Q4 2025 at Moderna, down from $9.4 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $19.0 billion in Q1 2023 to a low of $3.2 billion in Q1 2021.
  • A 5-year average of $12.1 billion and a median of $12.2 billion in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 387.89% in 2022, then tumbled 61.58% in 2025.
  • Moderna's Equity Average stood at $12.1 billion in 2021, then skyrocketed by 52.93% to $18.6 billion in 2022, then decreased by 26.42% to $13.7 billion in 2023, then decreased by 16.41% to $11.4 billion in 2024, then decreased by 21.24% to $9.0 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Equity Average are $9.0 billion (Q4 2025), $9.4 billion (Q3 2025), and $4.7 billion (Q2 2025).